Navigation Links
NexGen Biofuels Ltd. Announces Trading on OTC Bulletin Board
Date:3/20/2008

WESLEY CHAPEL, Florida, March 20 /PRNewswire-FirstCall/ -- NexGen Biofuels Ltd. (OTC:NXGNF) announced today that effective as of March 17, 2008, its ordinary shares have been approved for quotation on the OTC-Bulletin Board under the symbol NXGNF.

NexGen is a development stage company that is currently seeking to develop and/or acquire ethanol and bio-diesel plants and blending assets in the United States.

For More Information On NexGen Biofuels, Visit http://www.nexgenbiofuels.net.

Safe Harbor: This press release contains certain forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward looking statement made by or on behalf of NexGen Biofuels Ltd. Readers are referred to the documents filed by the company with the Securities And Exchange Commission, specifically the form 8-K/A filed on February 12, 2008 that identifies important risks which could cause actual results to differ from those contained in the forward looking statements.

Contact: Eran Rotem CFO

+972-3-9277232


'/>"/>
SOURCE NexGen Biofuels Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
2. NexGenix Pharmaceuticals Enters into Exclusive World-wide License to Develop Novel Hsp90 Inhibitors
3. Healthcare Announced That an Overwhelming Majority of its Shareholders Approved the NexGen Biofuels Transaction
4. Healthcare Technologies Ltd. Announces the Change of its Name to "NexGen Biofuels Ltd"
5. NexGen Biofuels Ltd. (Nasdaq: NXGN) Announces Receipt of Nasdaq Delisting Determination
6. N.C. Takes Biofuels Leadership, Establishes New Endeavor With $5 Million State Appropriation
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
9. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
10. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
11. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... -- Financial Highlights ... unaudited)Three Months Ended December 31,Twelve Months Ended December 31,20162015% ... $           300$   ... Product Revenue 3539(10)%9498(4)%Kuvan Net Product ... 756025%297303(2)%Vimizim Net Product Revenue ...
(Date:2/23/2017)... 2017  MIODx announced today that it has ... technologies from the University of California, San Francisco ... monitor a patient for response to immune checkpoint ... second license extends the technology with a method ... have an immune-related adverse event (IRAE) from their ...
(Date:2/23/2017)... 2017  Imanis Life Sciences announced today the ... vaccinia viruses for virotherapy research. These viruses are ... proprietary, vaccinia virus-based technology platform for research use. ... a partnership with Genelux to offer researchers, for ... use in research," said Dr. Kah Whye ...
(Date:2/23/2017)... ... 2017 , ... David Nolte, PhD accepted Purdue University’s 2016 ... Research Park of West Lafayette, Indiana. , The top commercialization award is ... success with, commercializing discoveries from Purdue research. “This award is truly an honor. ...
Breaking Biology Technology:
(Date:2/21/2017)... , February 21, 2017 Der ... US-Dollar wachsen. Nach einem Gespräch mit mehr als 50 Vertretern ... Hindernisse zu überwinden gilt, um diese Prognose zu realisieren. ... ... die Mobilisierung der finanziellen Mittel für die Biobank, die ...
(Date:2/10/2017)... 10, 2017 Research and Markets ... "Personalized Medicine - Scientific and Commercial Aspects" to their ... ... is integrated with therapy for selection of treatment as well ... and prevention of disease in modern medicine. Biochip/microarray technologies and ...
(Date:2/8/2017)... The biometrics market has reached a ... organizations, desires to better authenticate or identify users ... challenge questions), biometrics is quickly working its way ... is driven by use cases, though there traditionally ... uses cases, with consumer-facing use cases encompassing authentication, ...
Breaking Biology News(10 mins):